ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1656

Whole-Exome Sequencing as a Predictive Tool for Severe CAKUT

Session Information

Category: Genetic Diseases of the Kidneys

  • 1002 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Harris, Meredith, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
  • Erkan, Elif, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
  • Kaufman, Kenneth, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Background

Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) represent about 1% of births, with about 20% secondary to genetic causes. The Cincinnati Fetal Center is one of the few centers worldwide offering fetal interventions including amnioinfusion and for infants with oligo/anhydramnios. As these infants are phenotypically severe, we predict they will be genetically enriched. We hypothesize that identifying novel genetic variants in infants with CAKUT will aid in determination of clinical course and improve parental counseling.

Methods

We collected blood from infants whose mothers underwent fetal interventions for oligo/anhydramnios for the purpose of Whole Exome Sequencing as well as blood samples from parents for trios testing.

Results

We completed variant calling for 2 singletons and 1 maternal sample. Both patients’ mothers underwent multiple amnioinfusions, and the patients required initiation of RRT within week 1 of life. In both patients, we identified a nonsynonymous SNV of HSPG2 on chromosome 1. HSPG2 encodes for perlecan, which has a role in renal embryogenesis, specifically the maturation of the epithelial and mesenchymal tissues of the kidney. We identified a rare heterozygous variant found in 0.28% of the population in 1 patient. In the other patient, we identified 2 variants, which form a state of compound heterozygosity. We found a rare heterozygous nonsynonymous SNV mutation in T-Box Transcription Factor-18 (TBX18) in 1 sample. TBX18 is imperative for the development of ureteric mesenchyme and is expressed in the renal capsule and glomerular mesangial cells. This patient had bilateral VUR and dysplastic kidneys. The other patient had a rare heterozygous nonsynonymous SNV in the transcriptional repressor GLI3 which is implicated in renal morphogenesis. Variants in GLI3 have been described in renal dysplasia and aplasia. This patient was born with bilateral multicystic dysplastic kidneys.

Conclusion

In our pilot data of WES of 2 singletons and 1 maternal sample, we report 3 candidate genes, HSPG2, TBX18, and GLI3, all of which are necessary for renal and urinary tract development, specifically glomerular and ureteric development and transcriptional regulation. In a small cohort, we demonstrate that WES of a severely affected population provides insight into the molecular mechanisms underlying CAKUT, which can aid in prognosis and parental counseling in the future.

Funding

  • Other NIH Support